Table I.

Main features of the Italian Platelet Technology Assessment Study (IPTAS).

Two non-inferiority randomised clinical trials carried out in parallel with a common protocol in onco-haematology platelet recipients.

Pathogen reduced platelets in additive solution vs standard platelets in additive solution.

Three clinical centres using the Intercept® technology; three clinical centres using the Mirasol® technology.

Primary end point: percent of patients with WHO grade 2 or greater bleeding.

Secondary end points: post-transfusion platelet count increments, blood component use; transfusion reactions and adverse events; mortality.

IPTAS biorepository including patient’s plasma and buffy coat collected at each transfusion and segments of standard and pathogen reduced blood components transfused during the study.

WHO: World Health Organization.